GB202112935D0 - Sars-cov-2 (sars2, covid-19) heavy chain only antibodies - Google Patents

Sars-cov-2 (sars2, covid-19) heavy chain only antibodies

Info

Publication number
GB202112935D0
GB202112935D0 GBGB2112935.8A GB202112935A GB202112935D0 GB 202112935 D0 GB202112935 D0 GB 202112935D0 GB 202112935 A GB202112935 A GB 202112935A GB 202112935 D0 GB202112935 D0 GB 202112935D0
Authority
GB
United Kingdom
Prior art keywords
sars2
covid
cov
sars
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2112935.8A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Erasmus University Medical Center
Universiteit Utrecht Holding BV
Harbour Antibodies BV
Original Assignee
Erasmus University Medical Center
Universiteit Utrecht Holding BV
Harbour Antibodies BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erasmus University Medical Center, Universiteit Utrecht Holding BV, Harbour Antibodies BV filed Critical Erasmus University Medical Center
Priority to GBGB2112935.8A priority Critical patent/GB202112935D0/en
Publication of GB202112935D0 publication Critical patent/GB202112935D0/en
Priority to PCT/EP2022/075300 priority patent/WO2023036986A2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
GBGB2112935.8A 2021-09-10 2021-09-10 Sars-cov-2 (sars2, covid-19) heavy chain only antibodies Ceased GB202112935D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2112935.8A GB202112935D0 (en) 2021-09-10 2021-09-10 Sars-cov-2 (sars2, covid-19) heavy chain only antibodies
PCT/EP2022/075300 WO2023036986A2 (en) 2021-09-10 2022-09-12 Sars-cov-2 (sars2, covid-19) heavy chain only antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2112935.8A GB202112935D0 (en) 2021-09-10 2021-09-10 Sars-cov-2 (sars2, covid-19) heavy chain only antibodies

Publications (1)

Publication Number Publication Date
GB202112935D0 true GB202112935D0 (en) 2021-10-27

Family

ID=78149362

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2112935.8A Ceased GB202112935D0 (en) 2021-09-10 2021-09-10 Sars-cov-2 (sars2, covid-19) heavy chain only antibodies

Country Status (2)

Country Link
GB (1) GB202112935D0 (en)
WO (1) WO2023036986A2 (en)

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
WO1988001513A1 (en) 1986-08-28 1988-03-10 Teijin Limited Cytocidal antibody complex and process for its preparation
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP0752248B1 (en) 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
CA2183667A1 (en) 1994-02-22 1995-08-24 Wayne A. Marasco Nucleic acid delivery system, method of synthesis and uses thereof
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
SG188080A1 (en) 2004-07-22 2013-03-28 Univ Erasmus Medical Ct Binding molecules
EP1991580A2 (en) 2006-01-25 2008-11-19 Erasmus University Medical Center Rotterdam Generation of heavy-chain only antibodies in transgenic animals
KR101711222B1 (en) 2008-12-18 2017-02-28 에라스무스 유니버시티 메디컬 센터 로테르담 Non-human transgenic animals expressing humanised antibodies and use therof
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
EP2967012B1 (en) 2013-03-14 2020-09-16 Erasmus University Medical Center Rotterdam Transgenic non-human mammal for antibody production
US10993420B2 (en) 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
US9111624B2 (en) 2013-03-22 2015-08-18 Katsuyuki Fujita Semiconductor memory device
KR102406171B1 (en) 2017-11-09 2022-06-10 삼성전자주식회사 Compressor
CN112094342B (en) * 2020-09-25 2022-05-13 中国科学技术大学 Alpaca source nano antibody combined with SARS-CoV-2RBD

Also Published As

Publication number Publication date
WO2023036986A2 (en) 2023-03-16
WO2023036986A3 (en) 2023-04-20

Similar Documents

Publication Publication Date Title
GB202101720D0 (en) Sars-cov-2 (sars2, covid-19) antibodies
SI3872091T1 (en) Antibodies against sars-cov-2
IL286398A (en) Heavy chain antibodies binding to psma
EP3808520C0 (en) Chain saw
EP3807061A4 (en) Block chain with monolithic links
GB202112935D0 (en) Sars-cov-2 (sars2, covid-19) heavy chain only antibodies
IL300142A (en) ANTI-IL13Ralpha2 ANTIBODIES
GB202105110D0 (en) Anti-CD73 antibodies
EP3997016A4 (en) Novel chain link
GB202014851D0 (en) SARS-COV-2 antibodies
GB202015115D0 (en) ZIP12 Antibody
GB202008860D0 (en) BTLA antibodies
PL4045714T3 (en) Link for an excavating chain, and associated excavating chain
IL311043A (en) Anti-il-11rα antibodies
GB202208773D0 (en) Anti-SARS2-S antibodies
IL308782A (en) Antibodies
IL308100A (en) Antibodies
GB202116709D0 (en) Antibodies
GB202112297D0 (en) Antibodies
GB202111905D0 (en) Antibodies
IL299767A (en) Anti-αlpha-4-βeta-7 antibodies
GB202104128D0 (en) Antibodies
GB202102401D0 (en) Antibodies
GB202102227D0 (en) Antibodies
GB202101578D0 (en) Antibodies

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)